IL-10 and Coordinated Cytokine Responses Predict Rapid HIV Reservoir Decay in Acute Treated HIV Infection
Barbehenn, A.; Shi, L.; Shao, J.; Hoh, R.; Hartig, H. M.; Pae, V.; Sarvadhavabhatla, S.; Donaire, M. S.; Sheikhzadeh, C. H.; Savur, S.; Milush, J.; Laird, G. M.; Mathias, M.; Ritter, K.; Martin, J.; Hecht, F.; Pilcher, C.; Cohen, S. E.; Buchbinder, S.; Havlir, D.; Gandhi, M.; Henrich, T. J.; Hatano, H.; Ribeiro, S. P.; Tomalka, J. A.; Deeks, S. G.; Sekaly, R. P.; Wang, J.; Hudson, A.; Lee, S. A.
Show abstract
Background: The HIV reservoir is established within days of infection and persists despite antiretroviral therapy (ART). However, data describing early reservoir decay dynamics and the host immune responses associated with this process remain limited. Methods: We analyzed more than 500 longitudinal blood samples from 67 individuals treated during acute HIV infection. Plasma cytokines and HIV reservoir size (intact and defective DNA) were quantified. Associations between immune markers and reservoir decay following ART initiation were assessed using unsupervised clustering, mixed-effects linear spline models, and nonlinear modeling. Results: Higher levels of IFN-{gamma}, IL-10, IL-18, and TNF- during weeks 24-52 of ART were associated with significantly faster decay of both intact and defective HIV DNA. These relationships were independent of ART initiation timing (days since infection), baseline viremia, initial CD4+ T cell count, and longitudinal CD4:CD8 ratio. Among these cytokines, IL-10 demonstrated the strongest association with accelerated reservoir decay, despite prior evidence linking it to larger reservoirs in SIV models. Discussion: These findings highlight the pleiotropic and stage-dependent roles of cytokines across acute to later stages of HIV, suggesting that a coordinated balance between immune activation and regulation of inflammation may promote early HIV reservoir decay.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir size 95%
- No Evidence that Ongoing HIV-Specific Immune Responses Contribute to Persistent Inflammation and Immune Activation in Persons on Long-Term ART 95%
- A Moving Target: Impacts of Lowering Viral Load Suppression Cutpoints on Progress Towards HIV Epidemic Control Goals 92%
Similar papers in this journal
- Healthy dynamics of CD4 T cells may drive HIV resurgence in perinatally-infected infants on antiretroviral therapy 95%
- HIV proviral genetic diversity, compartmentalization and inferred dynamics in lung and blood during long-term suppressive antiretroviral therapy 95%
- Quantifying prevalence and risk factors of HIV multiple infection in Uganda from population-based deep-sequence data 94%
Similar papers in this journal
- Differences in HIV-1 reservoir size, landscape characteristics and decay dynamics in acute and chronic treated HIV-1 Clade C infection 97%
- Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels as compared with therapy based on protease inhibitors 97%
- Deep-sequence phylogenetics to quantify patterns of HIV transmission in the context of a universal testing and treatment trial – BCPP/ Ya Tsie trial 94%
Similar papers in this journal
- SARS-CoV-2 evolution and patient immunological history shape the breadth and potency of antibody-mediated immunity 90%
- People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses 90%
- Viral genetic determinants of prolonged respiratory syncytial virus infection among infants in a healthy term birth cohort 90%
Similar papers in this journal
- Single-dose effectiveness of mpox vaccine in Quebec, Canada: test-negative design with and without adjustment for self-reported exposure risk 91%
- Household transmission of SARS-CoV-2 from adult index cases living with and without HIV in South Africa, 2020-2021: a case-ascertained, prospective observational household transmission study 91%
- Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.